Defining the window of opportunity for post-transplant ThINKK therapy and TRAIL as a biomarker of NK cell response.
Researchers identified timing and biomarkers for adoptive cell therapy after stem cell transplant in children with hard-to-treat cancers.
Cancer relapse is still the first cause of death following hematopoietic stem cell transplantation (HSCT) in children with refractory cancers. These data pave the way toward adoptive transfers of ThINKK in the first months after transplant and confirms TRAIL as a biomarker for the future pharmacodynamics studies of our Phase 1 clinical trial.
What the study was
- Study design
- Phase 1 clinical trial
- Population
- Cancer/disease patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cytotherapy
Why it surfaced
Matched topic(s): Precision oncology and genomic medicine, Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Phase 1 clinical trial. Score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.